Trial reportThe New England journal of medicine2018
Mifepristone Pretreatment for the Medical Management of Early Pregnancy Loss.
Trial report in The New England journal of medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02012491 (Comparative Effectiveness of Pregnancy Failure Management Regimens), which is not on this map. Cited by 75 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparative Effectiveness of Pregnancy Failure Management Regimens
Who cites it
75 citing papers in PubMed, 4 syntheses or guidelines pooled it, 216 citations in OpenAlex.
- Inducing labor after fetal demise: a systematic review and meta-analysis of the efficacy and safety of mifepristone and misoprostol combination versus misoprostol alone.BMC pregnancy and childbirth · 2025Pooled it
- Medical methods for first trimester abortion.The Cochrane database of systematic reviews · 2022Pooled it
- Methods for managing miscarriage: a network meta-analysis.The Cochrane database of systematic reviews · 2021Pooled it
- Medical treatment for early fetal death (less than 24 weeks).The Cochrane database of systematic reviews · 2019Pooled it
- Ulipristal acetate for use in medical management of early pregnancy loss: a pilot feasibility study.BMC pregnancy and childbirth · 2026Trial
- Medical management of early pregnancy loss is cost-effective compared with office uterine aspiration.American journal of obstetrics and gynecology · 2022Trial
- Predicting the likelihood of successful medical treatment of early pregnancy loss: development and internal validation of a clinical prediction model.Human reproduction (Oxford, England) · 2022Trial
- Trial
- The effect of mifepristone pretreatment on bleeding and pain during medical management of early pregnancy loss.Contraception · 2021Trial
- Timing and efficacy of mifepristone pretreatment for medical management of early pregnancy loss.Contraception · 2021Trial
- Mifepristone and misoprostol versus misoprostol alone for the management of missed miscarriage (MifeMiso): a randomised, double-blind, placebo-controlled trial.Lancet (London, England) · 2020Trial
- Pregnancy intentions and contraceptive uptake after miscarriage.Contraception · 2020Trial
- Cost-effectiveness of Mifepristone Pretreatment for the Medical Management of Nonviable Early Pregnancy: Secondary Analysis of a Randomized Clinical Trial.JAMA network open · 2020Trial
- Zinc Exposure Causes Disulfidptosis to Induce Miscarriage by Up-Regulating GATA1/METTL1/SLC7A11 Axis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Is a history of cesarean section a predictive factor for the failure of medical management in spontaneous abortion?Archives of gynecology and obstetrics · 2026Article
- Post protocol residual thickness as a negative predictor for pharmacological treatment in early pregnancy loss.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026Article
- Medication Management of Early Pregnancy Loss in an Urban Texas Emergency Department.Academic emergency medicine : official journal of the Society for Academic Emergency Medicine · 2026Article
- Short-term hormonal modulation with mifepristone does not induce oncogenic changes in the endometrium of BRCA1/2 pathogenic variant carriers.Communications medicine · 2026Article
- Outcomes of medical management of miscarriage in an early pregnancy setting.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026Observational
- Bisphenol B Exposure Induces Miscarriage by Suppressing Migration/Invasion and Migrasome Formation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundMedical management of early pregnancy loss is an alternative to uterine aspiration, but standard medical treatment with misoprostol commonly results in treatment failure. We compared the efficacy and safety of pretreatment with mifepristone followed by treatment with misoprostol with the efficacy and safety of misoprostol use alone for the management of early pregnancy loss.
methodsWe randomly assigned 300 women who had an anembryonic gestation or in whom embryonic or fetal death was confirmed to receive pretreatment with 200 mg of mifepristone, administered orally, followed by 800 μg of misoprostol, administered vaginally (mifepristone-pretreatment group), or 800 μg of misoprostol alone, administered vaginally (misoprostol-alone group). Participants returned 1 to 4 days after misoprostol use for evaluation, including ultrasound examination, by an investigator who was unaware of the treatment-group assignments. Women in whom the gestational sac was not expelled were offered expectant management, a second dose of misoprostol, or uterine aspiration. We followed all participants for 30 days after randomization. Our primary outcome was gestational sac expulsion with one dose of misoprostol by the first follow-up visit and no additional intervention within 30 days after treatment.
resultsComplete expulsion after one dose of misoprostol occurred in 124 of 148 women (83.8%; 95% confidence interval [CI], 76.8 to 89.3) in the mifepristone-pretreatment group and in 100 of 149 women (67.1%; 95% CI, 59.0 to 74.6) in the misoprostol-alone group (relative risk, 1.25; 95% CI, 1.09 to 1.43). Uterine aspiration was performed less frequently in the mifepristone-pretreatment group than in the misoprostol-alone group (8.8% vs. 23.5%; relative risk, 0.37; 95% CI, 0.21 to 0.68). Bleeding that resulted in blood transfusion occurred in 2.0% of the women in the mifepristone-pretreatment group and in 0.7% of the women in the misoprostol-alone group (P=0.31); pelvic infection was diagnosed in 1.3% of the women in each group.
conclusionsPretreatment with mifepristone followed by treatment with misoprostol resulted in a higher likelihood of successful management of first-trimester pregnancy loss than treatment with misoprostol alone. (Funded by the National Institute of Child Health and Human Development; PreFaiR ClinicalTrials.gov number, NCT02012491 .).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.